妊娠相关药代动力学变化:系统综述
该系统综述检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和Web of Science,纳入198项研究、涉及121种药物,比较妊娠与非妊娠人群的药代动力学。妊娠相关药代动力学变化常表现为药物消除增强和总药物暴露降低,但临床反应与结局的改变仍大多未知。
要点
- 妊娠期药代动力学变化常表现为药物消除增强和总药物暴露降低。
- 常见研究药物类别包括抗逆转录病毒药、抗癫痫药、抗生素、抗疟药和心血管药。
- 药代动力学变化对应的临床反应与结局改变仍大多未知。
核心结论
- 妊娠相关药代动力学变化的知识不断积累,但其对母亲和胎儿的临床影响仍存在显著认知差距。
- 临床医生必须了解这些妊娠期特有的药代动力学变化,并审慎评估其临床意义。
研究设计与样本
- 系统检索MEDLINE(Ovid)、Embase(Ovid)、Cochrane Central Register of Controlled Trials(Ovid)和Web of Science(Thomson Reuters),从数据库建库至2015年8月31日,并于2015年9月1日至2016年5月20日进行更新检索。
- 纳入标准为涉及一组孕妇并与非妊娠参与者或非妊娠人群数据比较的临床药代动力学研究,无语言或日期限制。
- 共纳入198项研究,涉及121种不同药物。
主要发现
- 常见研究药物类别包括抗逆转录病毒药(54项研究)、抗癫痫药(27项研究)、抗生素(23项研究)、抗疟药(22项研究)和心血管药(17项研究)。
- 妊娠相关药代动力学参数变化常表现为药物消除增强和给定剂量下总药物(与血浆蛋白结合及未结合)暴露降低。
- 相关的临床反应与结局改变或缺乏改变仍大多未知。
临床怎么用
- 临床医生必须了解妊娠期特有的药代动力学变化,并审慎评估其临床意义。
局限性
- 妊娠相关药代动力学变化对应的临床反应与结局改变或缺乏改变仍大多未知。
- 妊娠期药代动力学变化知识与对其临床影响的理解之间存在显著差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women are commonly prescribed a variety of medications during pregnancy. As most organ systems are affected by the substantial anatomical and physiological changes that occur during pregnancy, it is expected that pharmacokinetics (PK) (absorption, distribution, metabolism, and excretion of drugs) would also be affected in ways that may necessitate changes in dosing schedules. The objective of this study was to systematically identify existing clinically relevant evidence on PK changes during pregnancy. METHODS AND FINDINGS: Systematic searches were conducted in MEDLINE (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (Ovid), and Web of Science (Thomson Reuters), from database inception to August 31, 2015. An update of the search from September 1, 2015, to May 20, 2016, was performed, and relevant data were added to the present review. No language or date restrictions were applied. All publications of clinical PK studies involving a group of pregnant women with a comparison to nonpregnant participants or nonpregnant population data were eligible to be included in this review. A total of 198 studies involving 121 different medications fulfilled the inclusion criteria. In these studies, commonly investigated drug classes included antiretrovirals (54 studies), antiepileptic drugs (27 studies), antibiotics (23 studies), antimalarial drugs (22 studies), and cardiovascular drugs (17 studies). Overall, pregnancy-associated changes in PK parameters were often observed as consistent findings among many studies, particularly enhanced drug elimination and decreased exposure to total drugs (bound and unbound to plasma proteins) at a given dose. However, associated alterations in clinical responses and outcomes, or lack thereof, remain largely unknown. CONCLUSION: This systematic review of pregnancy-associated PK changes identifies a significant gap between the accumulating knowledge of PK changes in pregnant women and our understanding of their clinical impact for both mother and fetus. It is essential for clinicians to be aware of these unique pregnancy-related changes in PK, and to critically examine their clinical implications.
引用
- Pariente G, Leibson T, Carls A, et al. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016. PMID: 27802281. doi:10.1371/journal.pmed.1002160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。